ERBB2 and breast cancer: Importantly, three-dimensional (3D) cell culture experiments demonstrated that adding ICIs (Nivolumab (N) and Ipilimumab (I)) to the triple-targeting regimen further reduced cell viability in HER2<sup>+</sup> BC cells.